SCHEMBL26419986

SCHEMBL26419986

COc1ccc(C(OC[C@H]2O[C@@H](n3cnc4c(N(Cc5ccccc5)C(=O)COc5ccccc5)ncnc43)C(OC)C2OP(OCCC#N)N(C(C)C)C(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 10/20 0.40
▸ TRDMT1 O14717 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ NPEPPS P55786 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ ANPEP P15144 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ ADORA2A P29274 1/20 0.32
▸ ADORA2B P29275 1/20 0.32
▸ ADORA1 P30542 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26419981 1.00 TYMP (0.40) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26419399 1.00 TYMP (0.40) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26420042 0.97 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26419432 0.97 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26420049 0.97 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26420084 0.96 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26419440 0.96 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26420070 0.96 TYMP (0.39) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26419422 0.95 TYMP (0.38) TYMPTRDMT1SMN1; SMN2NPEPPSTP53
SCHEMBL26420015 0.95 TYMP (0.38) TYMPTRDMT1SMN1; SMN2NPEPPSTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130423-A1 NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE UNIWERSYTET WARSZAWSKI (PL) 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130423-A1 NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE RNGTT, RNMT, NSUN3 TYMP 808/4885TRDMT1 14/4885SMN1; SMN2 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback